Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury.
Daniela LeccaShih-Chang HsuehWeiming LuoDavid TweedieDong Seok KimAbdul Mannan BaigNeil VargessonYu Kyung KimInho HwangSun KimBarry J HofferYung-Hsiao ChiangNigel H GreigPublished in: Journal of biomedical science (2023)
TFBP and TFNBP represent a new class of thalidomide-like IMiDs that lower proinflammatory cytokine generation but lack binding to cereblon, the main teratogenicity-associated mechanism. This aspect makes TFBP and TFNBP potentially safer than classic IMiDs for clinical use. TFBP provides a strategy to mitigate excessive neuroinflammation associated with moderate severity TBI to, thereby, improve behavioral outcome measures and warrants further investigation in neurological disorders involving a neuroinflammatory component.
Keyphrases
- brain injury
- cerebral ischemia
- subarachnoid hemorrhage
- traumatic brain injury
- oxidative stress
- high intensity
- weight gain
- severe traumatic brain injury
- dna binding
- lps induced
- adverse drug
- cognitive impairment
- radiation induced
- radiation therapy
- emergency department
- mild traumatic brain injury
- physical activity
- body mass index
- transcription factor